@s y d ne y .ed u .au @ Funding information 1 | BACKGROUND Ovarian cancer (OC) is the leading cause of death from gynaecological cancers in women [15, 36, 29] and the fifth most common cause of cancer deaths in women overall, with an estimated 239,000 new cases and over 152,000 deaths worldwide annually [10, 27]. It has a five year mortality rate in the United States of approximately 35% [12, 35] [3, 22].Current standard treatment mainly comprises platinum-based chemotherapeutics, with platinum drugs cisplatin and carboplatin given in combination with paclitaxel used to treat nearly all women with OC. However, the most prevalent OC type, high grade serous carcinoma (HGSC), often develops significant chemotherapy resistance alongside greatly altered genomes and transcriptome. Thus, most patients initially respond to the treatment, but over the longer term